Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:10 AM
Ignite Modification Date:
2025-12-25 @ 2:10 AM
NCT ID:
NCT05157360
Brief Summary:
Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.
Detailed Description:
Primary outcome:
1\. Hospital survival
Secondary outcomes:
1. Duration of vasopressor therapy
2. Requirement for renal replacement therapy in patients with Acute Kidney Injury (AKI)
3. ICU length of stay (LOS)
4. Change in serum procalcitonin (PCT) over first 72 hours
5. Change in SOFA score over first 72 hours (measured as SOFA score daily for four days, with day one being admission, then 3 days after, totaling 4 days of treatment with HAT)
6. Procalcitonin clearance (formula = initial PCT - 72 hour PCT divided by initial PCT x 100)
7. Number of wound related surgeries
8. Wound status at time of hospital discharge:
1. Open
2. Closed
Study:
NCT05157360
Study Brief:
Protocol Section:
NCT05157360